Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia

被引：0
作者：
H. Donath
S. Woelke
R. Schubert
M. Kieslich
M. Theis
G. Auburger
R. P. Duecker
S. Zielen
机构：
[1] Goethe University,Division of Allergology, Pulmonology and Cystic Fibrosis, Department for Children and Adolescents
[2] Goethe University,Division of Pediatric Neurology, Department for Children and Adolescents
[3] Goethe University,Experimental Neurology, Medical School
来源：
The Cerebellum | 2022年 / 21卷
关键词：
Ataxia telangiectasia; Neurofilament light chain; NfL; Neurodegeneration; Disease progression; Biomarker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Ataxia telangiectasia (A-T) is a progressive and life-limiting disease associated with cerebellar ataxia due to progressive cerebellar degeneration. In addition to ataxia, which is described in detail, the presence of chorea, dystonia, oculomotor apraxia, athetosis, parkinsonism, and myoclonia are typical manifestations of the disease. The study aimed to evaluate the specificity and sensitivity of neurofilament light chain (NfL) as a biomarker of neurodegeneration in relation to SARA score. In this prospective trial, one visit of 42 A-T patients aged 1.3–25.6 years (mean 11.6 ± 7.3 years) was performed, in which NfL was determined from serum by ELISA. Additionally, a neurological examination of the patients was performed. Blood was collected from 19 healthy volunteers ≥ 12 years of age. We found significantly increased levels of NfL in patients with A-T compared to healthy controls (21.5 ± 3.6 pg/mL vs. 9.3 ± 0.49 pg/mL, p ≤ 0.01). There was a significant correlation of NfL with age, AFP, and SARA. NfL is a new potential progression biomarker in blood for neurodegeneration in A-T which increases with age.
引用
收藏
页码：39 / 47
页数：8
相关论文
共 459 条
[11]  
Schroeder SA(2018)Reconstitution of the ataxia-telangiectasia cellular phenotype with lentiviral vectors Front Immunol 9 2703-471
[12]  
Zielen S(2008)Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid amplicon vector Mol Ther 16 81-611
[13]  
Bhatt JM(2015)Synthesis of 6,8,9 poly-substituted purine analogue libraries as pro-apoptotic inducers of human leukemic lymphocytes and DAPK-1 inhibitors Org Biomol Chem 13 5224-257
[14]  
Bush A(2019)Genotype, extrapyramidal features, and severity of variant ataxia-telangiectasia Ann Neurol 85 170-676
[15]  
van Gerven M(2017)Ataxia-telangiectasia: immunodeficiency and survival Clin Immunol 178 45-129
[16]  
Nissenkorn A(2017)Ataxia telangiectasia in Turkey: multisystem involvement of 91 patients World J Pediatr 13 465-83
[17]  
Renke M(2006)Survival probability in ataxia telangiectasia Arch Dis Child 91 610-195
[18]  
Yarlett L(1975)Ataxia telangiectasia: some historic, clinical and pathological observations Birth Defects: Original Article Series II 1 255-1509
[19]  
Taylor M(1968)Pathological observations in ataxia-telangiectasia. A report of five cases J Neuropathol Exp Neurol 27 659-1720
[20]  
Tonia T(2012)Neurodegeneration in ataxia telangiectasia: what is new? What is evident? Neuropediatrics. 43 119-549
12345678910